Hypercapnic Respiratory Failure Clinical Trial
Official title:
Comparison of High Flow Nasal Cannula Oxygen and Conventional Oxygen Therapy on Ventilatory Support Duration During Acute-on-chronic Respiratory Failure: a Multicenter, Randomized, Controlled Trial
Chronic respiratory insufficiency and COPD are the third leading cause of death worldwide. Patients decompensate at various stages of their disease and exhibit acute-on-chronic respiratory failure (ACRF), a frequent cause of ICU hospitalization for hypercapnic acute respiratory failure (ARF). Non-invasive ventilation (NIV) is the first line ventilatory treatment for hypercapnic ARF. It is applied intermittently, separated by periods of spontaneous breathing (SB) with standard oxygen (O2). Standard O2 has drawbacks that limit the benefit of intermittent NIV in hypercapnic ARF: limited gas flow which is well below the patient's inspiratory flow rate, limited capacity and efficiency of oxygenation with non-controlled FiO2 (risk of excessive oxygen and induced hypercapnia), and cold and dry gas leading to discomfort and under-humidification of the airways and tracheobronchial secretions. Benefits in terms of work of breathing and CO2 removal resulting from PEEP and pressure support applied during NIV periods could be rapidly lost during standard O2. Recently, use of high-flow heated and humidified nasal oxygen therapy (HFHO) has gained enthusiasm among intensivists to manage ARF. HFHO delivers high flows (up to 60L/min, that generate moderate PEEP) of heated and humidified oxygen at a controlled and adjustable FiO2 (21 to 100%) that rapidly improve respiratory distress symptoms, oxygenation, respiratory comfort and outcome of patients with hypoxemic ARF. These unique features of HFHO could overcome some of the drawbacks of standard O2 during SB periods in hypercapnic ARF. Indeed, PEEP effect, washout of nasopharyngeal dead-space limiting CO2 re-breathing and inspired gas conditioning preserving adequate mucosal function and secretion removal, could potentially contribute to decrease airways resistance, intrinsic PEEP and work of breathing, while improving patient comfort. Investigators aim to determine if the use of HFHO, as compared to standard O2, increases the number of ventilator-free days (VFDs) and alive at day 28 in patients with hypercapnic ARF admitted in an ICU, an intermediate care, or a respiratory care unit, and requiring NIV.
In both groups, treatment will start with a first NIV session of 2 hours, with arterial blood gas measurement between one hour and two hours after initiating the NIV session. The NIV will be extended for those patients with a pH < 7.30. In both groups, patients will be assessed for their tolerance of NIV and their ability to switch to spontaneous breathing every hour +/- 30 min, except during sleep (10 pm-8 am); they will be assessed for their tolerance of spontaneous breathing and for the need of resumption of NIV every 2 hours+/- 30 min and every 4 +/- 1 hours thereafter. To ensure the consistency of indications of NIV and invasive mechanical ventilation (IMV) across centers and reduce potential bias, NIV and IMV will be initiated and stopped in the same way in the two groups, using predefined criteria. - Inclusion (day 0): informed consent, randomisation (HFHO group/standard O2 group), NIV initiation (for 2 hours), clinical and paraclinical exam including ABG, data collection - Follow-up (day 1 to day 28) : NIV, clinical exam, ABG, data collection ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02845076 -
Weaning From Noninvasive Ventilation
|
N/A | |
Recruiting |
NCT05008211 -
Information-Motivation-Behavioral Skills Model-based Intervention to Domiciliary Non-invasive Ventilation of Patients
|
N/A | |
Recruiting |
NCT03238339 -
The Clinical Application and Popularization of Portable Home Noninvasive Ventilator
|
||
Recruiting |
NCT06047405 -
NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP
|
N/A | |
Completed |
NCT04108819 -
Ketogenic Diet for Obesity Hypoventilation Syndrome
|
N/A | |
Recruiting |
NCT02874339 -
High Flow Nasal Oxygen Versus VNI in Acute Hypercapnic Cardiogenic Pulmonary Edema
|
N/A | |
Not yet recruiting |
NCT05497986 -
Conventional Low Flow Oxygenation Versus High Flow Nasal Cannula in Hypercapnic Respiratory Failure
|
N/A | |
Completed |
NCT01987661 -
The Effects of Airtrapping on Sleep and Breathing in Non Invasive Ventilation (NIV) in COPD
|
N/A | |
Completed |
NCT03398239 -
Comparison of BPAP ST/T and BPAP ST / T Mode With AVAPS for Hypercapnic Respiratory Failure in ED
|
N/A | |
Terminated |
NCT03353064 -
Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure
|
N/A | |
Completed |
NCT04072848 -
Mathematically Arterialised Testing of Hypercapnic Subjects Study
|
||
Not yet recruiting |
NCT04131660 -
Efficacy of Volume Ventilation in Patients With Acute Respiratory Failure at Risk of Obstructive Apneas or Obesity Hypoventilation
|
N/A | |
Completed |
NCT02699112 -
Cardiac and Respiratory Function With Non-invasive Ventilation
|
||
Completed |
NCT01523470 -
Withdrawal of Non-invasive Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Acute Hypercapnic Respiratory Failure
|
Phase 3 | |
Active, not recruiting |
NCT04709562 -
Clinical Stabilization of Hypercapnia: NIPPV v HVNI
|
N/A | |
Not yet recruiting |
NCT06064409 -
Optimal Timing and Failure Prediction of High Flow Nasal Cannula Oxygen Therapy in Emergency Department: Prospective Observational Single Center Study
|
||
Recruiting |
NCT04351906 -
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
|
N/A | |
Not yet recruiting |
NCT06367686 -
Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor
|
||
Active, not recruiting |
NCT03364946 -
High Flow Therapy in ICUs Across Ibero America
|
||
Not yet recruiting |
NCT06257667 -
Treatment of Acute Hypercapnic Respiratory Failure With OptiflowTM or Optiflow+DuetTM Nasal Cannula in COPD-patients
|
N/A |